SK Biopharm secures $70.25M XCOPRI supply deal
에스케이바이오팜
326030
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=865
Risk-adjusted indicator based on 865 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Contract Amount: 99.42 Billion KRW (USD 70.25 Million)
- • Contract as % of 2025 Revenue: 14.1%
- • Contract Period: August 18, 2026 – August 27, 2026
- • Payment Terms: Within 120 days after delivery
AI Analysis Summary
SK Biopharmaceuticals Co., Ltd. has signed a supply contract worth 99.42 billion KRW (USD 70.25 million) with its subsidiary, SK Life Science, Inc., for the epilepsy drug cenobamate (XCOPRI®) for the US market. This contract represents 14.1% of the company's 2025 consolidated revenue. The contract period is short, from August 18, 2026, to August 27, 2026. As an internal transaction, it will not be recognized as revenue on the consolidated financial statements, leading to a neutral financial impact.
How This Event Is Evaluated
Strategic Contract Evaluation
Contract events are evaluated by measuring business scale, revenue relevance, counterparty quality, and execution visibility.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Contract size relative to company revenue
- Expected revenue impact
- Counterparty quality
- Contract duration and execution period
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.